BioMarin Pharmaceutical Inc. (BMRN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

SA Transcripts 162.14K Followers Follow BioMarin Pharmaceutical Inc. ( BMRN ) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 3:00 PM EDT Company Participants Gregory Friberg - Executive VP and Chief Research & Development Officer Cristin Hubbard - Executive VP & Chief Commercial Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Wells Fargo Securities, LLC, Research Division Great. Thank you so much for joining us for this afternoon session. My name is Mohit Bansal. I'm one of the biotech and pharma analysts here at Wells Fargo. And I'm joined by Team BioMarin with us today. So we have Greg Friberg with us, the Head of R&D at BioMarin, and then Cristin Hubbard, she's the Head of Commercial at BioMarin. Thank you very much for joining us today. Gregory Friberg Executive VP and Chief Research & Development Officer Thanks for inviting us. Question-and-Answer Session Mohit Bansal Wells Fargo Securities, LLC, Research Division Awesome. So maybe let's just start with big picture. There has been a lot of development at BioMarin since you both joined. So what makes you excited about all the accomplishments in the last 1 year or so? And tell us about the investment story at this point? Cristin Hubbard Executive VP & Chief Commercial Officer I'll start. Okay. Well, we are really excited at BioMarin. As you've mentioned, we've had a lot of updates over the last year, and I'd say the last couple of years. And I know you'll get into some of the R&D updates. But some of the things that we're really excited about is that when we look at our established business units, so we have 2 of them, one which we used to call enzyme therapies, but since the acquisition of Amicus, we're now calling it metabolic conditions. And we have a lot of exciting activity there.